Octagon Capital Advisors LP 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Octagon Capital Advisors LP disclosed 30 US equity positions worth $455.6m in its Q2 2025 13F filing. The largest position was DNTH at 9.6% of the reported book, followed by AVBP and VRNA. Against the Q1 2025 filing, it opened 3 new positions, added to 7 and reduced 12 among the top 30 holdings.
What did Octagon Capital Advisors LP own in Q2 2025? Top 30 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 9.6% | $43.6m | 2,341,667 | 0% | held |
| 2 | AVBP ARRIVENT BIOPHARMA INC | 9.3% | $42.4m | 1,946,054 | -6% | reduced | |
| 3 | VRNA VERONA PHARMA PLC | 7.0% | $31.9m | 337,000 | 55% | added | |
| 4 | TSHA TAYSHA GENE THERAPIES INC | Healthcare | 6.4% | $29.1m | 12,592,500 | 18% | added |
| 5 | SPRY ARS PHARMACEUTICALS INC | Healthcare | 5.2% | $23.6m | 1,350,000 | 116% | added |
| 6 | GOSS GOSSAMER BIO INC | Healthcare | 5.0% | $22.6m | 18,350,000 | 0% | held |
| 7 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 4.9% | $22.5m | 2,425,000 | 0% | held |
| 8 | MERUS N V | 4.5% | $20.5m | 389,000 | 26% | added | |
| 9 | TRVI TREVI THERAPEUTICS INC | Healthcare | 4.4% | $20.1m | 3,672,000 | 11% | added |
| 10 | COGT COGENT BIOSCIENCES INC | Healthcare | 4.4% | $19.8m | 2,763,000 | 0% | held |
| 11 | ATYR ATYR PHARMA INC | Healthcare | 4.3% | $19.4m | 3,820,000 | 8% | added |
| 12 | APLSUSD APELLIS PHARMACEUTICALS INC | 3.4% | $15.6m | 903,500 | -57% | reduced | |
| 13 | NUVB NUVATION BIO INC | Healthcare | 3.3% | $15.0m | 7,691,334 | -3% | reduced |
| 14 | TRML TOURMALINE BIO INC | 3.2% | $14.5m | 905,000 | 0% | held | |
| 15 | 4XC1 KALVISTA PHARMACEUTICALS INC | 3.2% | $14.4m | 1,273,333 | -7% | reduced | |
| 16 | BRD1EUR MIND MEDICINE MINDMED INC | 3.0% | $13.8m | 2,130,000 | -29% | reduced | |
| 17 | CNTA CENTESSA PHARMACEUTICALS PLC | 3.0% | $13.5m | 1,030,000 | -28% | reduced | |
| 18 | PHVS PHARVARIS N V | 2.6% | $11.8m | 672,595 | -13% | reduced | |
| 19 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 2.5% | $11.6m | 266,000 | – | new |
| 20 | ABVX ABIVAX SA | 2.1% | $9.7m | 1,267,000 | 3% | added | |
| 21 | DBVT DBV TECHNOLOGIES S A | 2.0% | $9.3m | 1,018,021 | – | new | |
| 22 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 1.7% | $7.7m | 1,115,000 | 0% | held |
| 23 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 1.5% | $7.0m | 148,000 | -50% | reduced |
| 24 | UNCY UNICYCIVE THERAPEUTICS INC | 1.0% | $4.8m | 1,000,000 | – | new | |
| 25 | NGNE NEUROGENE INC | 1.0% | $4.5m | 303,000 | 0% | held | |
| 26 | HELIX ACQUISITION CORP II | 0.6% | $2.7m | 250,000 | 0% | held | |
| 27 | MAZE MAZE THERAPEUTICS INC | 0.5% | $2.2m | 177,667 | -62% | reduced | |
| 28 | KLRS KALARIS THERAPEUTICS INC | 0.2% | $961.2k | 360,000 | -25% | reduced | |
| 29 | ERAS ERASCA INC | Healthcare | 0.2% | $889.0k | 700,000 | -86% | reduced |
| 30 | NUVATION BIO INC | 0.1% | $300.5k | 154,112 | -99% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.